Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Burdock Root

Innovative Hand Dryer Pilot To Help Combat HCAIs, UK
An innovative hand dryer aimed at cutting the risk of healthcare associated infections (HCAIs) has been launched for NHS trusts and healthcare organisations by NHS Supply Chain.
generic viagra online
APhA Submits Recommendations For The Term "Meaningful Use" In TheDevelopment Of Policy Related To Electronic Health Records
The American Pharmacists Association (APhA) submitted comments to the Office of the National Coordinator for Health Information Technology"s (ONC) request for feedback on determining criteria for the term "meaningful use" of electronic records (EHRs), prepared by ONC"s HIT Policy Committee.
News of the day
Alvarado Hospital Introduces New Program For Patients With Back, Neck And Spine Disorders
To improve access to highly specialized care and to further its commitment to patients suffering from spine-related disorders, Alvarado Hospital has opened the Advanced Spine Institute & Minimally Invasive Spine Center, a multi-specialty "one-stop" center dedicated to providing world-class care to patients with back, neck and complex spinal problems.
Nutrition

Theratechnologies Presents Results From A Pharmacokinetic/Phamacodynamic Evaluation Of Tesamorelin At The Endocrine Society's Annual Meeting

Theratechnologies (TSX:TH) announced today that results from a pharmacokinetic/pharmacodynamic (PK/PD) evaluation of tesamorelin were presented as a poster (Poster number: P3-641) at the Endocrine Society"s 91st Annual Meeting in Washington D.C. Tesamorelin is an analogue of the growth hormone releasing factor evaluated for the treatment of excess abdominal fat in HIV patients with lipodystrophy. The poster outlined the results of two Phase 1 studies performed to determine the PK/PD profiles of tesamorelin after single and multiple administrations of 2 mg of tesamorelin once daily for 14 consecutive days, in healthy volunteers and HIV-positive patients receiving a stable antiretroviral regimen. The results showed that tesamorelin"s PK/PD profiles were generally similar in both groups and suggest that there is a minimal impact on tesamorelin"s PK parameters and on the induction of the insulin-like growth factor (IGF-1) when tesamorelin is given to HIV-positive patients on antiretroviral therapy. Levels of IGF-1 at baseline were within normal range and comparable in both groups (healthy: 175 ng/mL; HIV+: 164 ng/mL). After 14 days of daily injection, a similar increase was observed in healthy volunteers and in HIV-positive patients (115% and 121%, respectively, compared to baseline). In both studies, the extent of absorption (AUC) and the maximal concentration (Cmax) were similar (approximately 700 pgò€¢h/mL and 2400 pg/ml for AUC and Cmax, respectively). The half-life of tesamorelin ranged between 13 to 38 minutes in both healthy volunteers and HIV-positive patients. The poster presented is now available on Theratechnologies" website at http://www.theratech.com About HIV-Associated Lipodystrophy Several factors including the antiretroviral drug regimen and the virus itself are thought to contribute to HIV-associated lipodystrophy, which is characterized by body composition changes, dyslipidemia and glucose intolerance. The changes in body composition include excess abdominal fat accumulation. There is currently no approved treatment available for the excess abdominal fat related to HIV-associated lipodystrophy, a condition that can stigmatize patients and discourage HIV treatment adherence. Theratechnologies


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009